| |
| |
|
| Insider
Information: |
Daly James M |
| Relationship: |
Director |
| City: |
Wilmington |
| State: |
DE |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
153,097 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,513,402 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
153,097 |
|
|
| Total
Value |
$1,513,402 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
4
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 32.7%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Incyte Corp |
INCY |
EVP, Chief Commercial ... |
2015-06-23 |
3,521 |
2014-02-13 |
0 |
Premium* |
|
|
Halozyme Therapeutics Inc |
HALO |
|
2023-08-14 |
20,503 |
2016-05-04 |
0 |
Premium* |
|
|
Acadia Pharmaceuticals Inc |
ACAD |
Director |
2023-06-01 |
18,002 |
2019-09-09 |
0 |
Premium* |
|
|
Bellicum Pharmaceuticals, Inc |
BLCM |
Director |
2023-01-03 |
109,873 |
2022-01-04 |
0 |
Premium* |
|
|
Madrigal Pharmaceuticals Inc |
MDGL |
Director |
2024-04-02 |
1,198 |
2024-04-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MDGL |
Madrigal Pharmaceuticals ... |
Director |
– • – |
2024-04-02 |
4 |
AS |
$243.26 |
$2,668,087 |
D/D |
(10,912) |
1,198 |
0 |
% |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Director |
– • – |
2024-04-02 |
4 |
OE |
$105.08 |
$1,146,633 |
D/D |
10,912 |
12,110 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Director |
– • – |
2024-04-01 |
4 |
AS |
$255.64 |
$5,550,544 |
D/D |
(21,577) |
1,198 |
0 |
% |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Director |
– • – |
2024-04-01 |
4 |
OE |
$100.45 |
$2,174,711 |
D/D |
21,577 |
22,775 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
|
– • – |
2023-08-14 |
4 |
S |
$43.74 |
$437,410 |
D/D |
(10,000) |
20,503 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
|
– • – |
2023-08-11 |
4 |
S |
$43.71 |
$437,110 |
D/D |
(10,000) |
30,503 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • – |
2023-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,552 |
18,002 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
|
– • – |
2023-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
8,065 |
40,503 |
0 |
- |
|
| BLCM |
Bellicum Pharmaceuticals,... |
Director |
– • – |
2023-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
60,414 |
109,873 |
0 |
- |
|
| BLCM |
Bellicum Pharmaceuticals,... |
Director |
– • – |
2022-09-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,082 |
49,459 |
0 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • – |
2022-06-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,391 |
9,450 |
0 |
- |
|
| BLCM |
Bellicum Pharmaceuticals,... |
Director |
– • – |
2022-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,377 |
14,377 |
0 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • – |
2021-06-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,059 |
3,059 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2021-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
5,230 |
26,232 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2020-11-25 |
4 |
S |
$40.41 |
$418,800 |
D/D |
(10,363) |
21,002 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2020-08-13 |
4 |
S |
$29.12 |
$999,893 |
D/D |
(34,337) |
31,365 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • – |
2020-05-11 |
4 |
S |
$51.13 |
$1,342,178 |
D/D |
(26,250) |
0 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • – |
2020-05-11 |
4 |
OE |
$25.24 |
$692,700 |
D/D |
26,250 |
26,250 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2020-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
8,829 |
65,702 |
0 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • – |
2019-09-09 |
4 |
S |
$37.79 |
$1,133,860 |
D/D |
(30,000) |
0 |
0 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • – |
2019-09-09 |
4 |
OE |
$17.52 |
$525,600 |
D/D |
30,000 |
30,000 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2019-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,173 |
56,873 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2018-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
10,363 |
44,700 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2017-05-04 |
4 |
A |
$0.00 |
$0 |
D/D |
14,135 |
34,337 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2016-05-04 |
4 |
A |
$0.00 |
$0 |
D/D |
20,202 |
20,202 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
